Drug Metabolism in Liver Disease

Overview

Journal J Clin Pathol Suppl (R Coll Pathol)

Specialty Pathology

Date 1975 Jan 1

PMID 783214

Citations 3

Authors

L F Prescott

J A Forrest

K K Adjepon-Yamoah

N D Finlayson

Affiliations

Soon will be listed here.

Citing Articles

N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive Review.

Licata A, Minissale M, Stankeviciute S, Sanabria-Cabrera J, Lucena M, Andrade R Front Pharmacol. 2022; 13:828565.

PMID: 36034775 PMC: 9399785. DOI: 10.3389/fphar.2022.828565.

Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan.

Sidharta P, Treiber A, Dingemanse J Clin Pharmacokinet. 2015; 54(5):457-71.

PMID: 25860376 PMC: 4412377. DOI: 10.1007/s40262-015-0255-5.

Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma.

Uccello M, Malaguarnera G, Pelligra E, Biondi A, Basile F, Motta M Indian J Med Paediatr Oncol. 2011; 32(2):71-5.

PMID: 22174493 PMC: 3237183. DOI: 10.4103/0971-5851.89775.

References

Nelson E . RATE OF METABOLISM OF TOLBUTAMIDE IN TEST SUBJECTS WITH LIVER DISEASE OR WITH IMPAIRED RENAL FUNCTION. Am J Med Sci. 1964; 248:657-9. DOI: 10.1097/00000441-196412000-00004. View

GILLETTE J . Factors affecting drug metabolism. Ann N Y Acad Sci. 1971; 179:43-66. DOI: 10.1111/j.1749-6632.1971.tb46890.x. View

Mawer G, MILLER N, Turnberg L . Metabolism of amylobarbitone in patients with chronic liver disease. Br J Pharmacol. 1972; 44(3):549-60. PMC: 1665818. DOI: 10.1111/j.1476-5381.1972.tb07292.x. View

Branch R, Herbert C, Read A . Determinants of serum antipyrine half-lives in patients with liver disease. Gut. 1973; 14(7):569-73. PMC: 1412804. DOI: 10.1136/gut.14.7.569. View

Levi A, Sherlock S, Walker D . Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet. 1968; 1(7555):1275-9. DOI: 10.1016/s0140-6736(68)92292-7. View

Prescott L, ROSCOE P, Wright N, Brown S . Plasma-paracetamol half-life and hepatic necrosis in patients with paracetamol overdosage. Lancet. 1971; 1(7698):519-22. DOI: 10.1016/s0140-6736(71)91125-1. View

Vorne M, Arvela P . Effect of carbon tetrachloride induced progressive liver damage on drug-metabolizing enzymes and cytochrome P-450 in rat liver. Acta Pharmacol Toxicol (Copenh). 1971; 29(5):417-27. DOI: 10.1111/j.1600-0773.1971.tb00616.x. View

Schoene B, Fleischmann R, Remmer H, von OLDERSHAUSEN H . Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur J Clin Pharmacol. 1972; 4(2):65-73. DOI: 10.1007/BF00562499. View

Lundbergh P, Strandell T . Changes in hepatic circulation at rest, during and after exercise in young males with infectious hepatitis compared with controls. Acta Med Scand. 1974; 196(4):315-25. DOI: 10.1111/j.0954-6820.1974.tb01017.x. View

10.

Groszmann R, Kotelanski B, Cohn J, Khatri I . Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease. Am J Med. 1972; 53(6):715-22. DOI: 10.1016/0002-9343(72)90188-x. View

11.

Cohn J, Khatri I, Groszmann R, Kotelanski B . Hepatic blood flow in alcoholic liver disease measured by an indicator dilution technic. Am J Med. 1972; 53(6):704-14. DOI: 10.1016/0002-9343(72)90187-8. View

12.

Elfstrom J, Lindgren S . Disappearance of phenazone from plasma in patients with obstructive jaundice. Eur J Clin Pharmacol. 1974; 7(6):467-71. DOI: 10.1007/BF00560360. View

13.

Klotz U, McHorse T, Wilkinson G, Schenker S . The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther. 1974; 16(4):667-75. DOI: 10.1002/cpt1974164667. View

14.

Adjepon-Yamoah K, Nimmo J, Prescott L . Gross impairment of hepatic drug metabolism in a patient with chronic liver disease. Br Med J. 1974; 4(5941):387-8. PMC: 1612505. DOI: 10.1136/bmj.4.5941.387. View

15.

Hepner G, Vesell E . Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med. 1974; 291(26):1384-8. DOI: 10.1056/NEJM197412262912605. View

16.

Hvidberg E, ANDREASEN P, Ranek L . Plasma half-life of phenylbutazone in patients with impaired liver function. Clin Pharmacol Ther. 1974; 15(2):171-7. DOI: 10.1002/cpt1974152171. View

17.

Thomson P, Melmon K, Richardson J, Cohn K, Steinbrunn W, Cudihee R . Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med. 1973; 78(4):499-508. DOI: 10.7326/0003-4819-78-4-499. View

18.

Reidenberg M, James M, Dring L . The rate of procaine hydrolysis in serum of normal subjects and diseased patients. Clin Pharmacol Ther. 1972; 13(2):279-84. DOI: 10.1002/cpt1972132279. View

19.

OMalley K, Crooks J, Duke E, Stevenson I . Effect of age and sex on human drug metabolism. Br Med J. 1971; 3(5775):607-9. PMC: 1798743. DOI: 10.1136/bmj.3.5775.607. View

20.

Fevery J, De Groote J . Conjugation of N-acetyl-p-aminophenol (N.A.P.A.) in adult liver patients. Acta Hepatosplenol. 1969; 16(1):11-8. View